Product
G1T38
2 clinical trials
8 indications
Indication
cancerIndication
Non-Small Cell LungIndication
lung cancerIndication
Lung CancerIndication
DuctalIndication
BreastIndication
Breast CancerIndication
Breast NeoplasmClinical trial
Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine FailureStatus: Active (not recruiting), Estimated PCD: 2023-06-01
Clinical trial
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)Status: Completed, Estimated PCD: 2021-12-14